Literature DB >> 22028236

Fingolimod treatment for multiple sclerosis patients What do we do with varicella?

Alexander Winkelmann, Micha Loebermann, Emil C Reisinger, Hans Peter Hartung, Uwe K Zettl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22028236     DOI： 10.1002/ana.22605

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  6 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

2.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 3.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

4.  [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

Review 5.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 6.  Multiple sclerosis treatment and infectious issues: update 2013.

Authors:  A Winkelmann; M Loebermann; E C Reisinger; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.